PosterSessionOnline

INTERNATIONAL LIVER CANCER ASSOCIATION

ILCA 2025 Annual Conference

19 - 21 November, 2025. Hong Kong

N. Poster

Poster title

Applicant name

Status


P-01	Molecular-based therapies for primary liver cancers: real-world data from 120 patients of the 2025 French Genomic Medicine Initiative	Claudia Campani	Received

P-02	Molecular characterization of hemochromatosis related hepatocellular carcinomas	Patricia de la Cruz-Ojeda	Received

P-03	Replication Stress Stratifies HCC Aggressiveness and Predicts ATR Inhibitor Sensitivity	Jing FANG	Received

P-04	Charting single-cell metabolism co-evolution during metastasis	Yingcheng Wu	Received

P-05	Mutant ß-catenin drives metabolic transformation in hepatocellular carcinoma.	Aikha Melissa Wong	Received

P-06	Effectiveness and safety of atezolizumab and bevacizumab plus TACE as conversion therapy for initially unresectable HCC in real-world clinical practice in China (TALENTRUE): a multicenter, retrospective, observational cohort study	Ming Kuang	Received

P-07	Phenotypic variation in circulating neutrophils predicts response to trans-arterial chemoembolization in patients with HCC	Salem Nizami	Received

P-08	MEFV dysfunction Promotes Hepatocellular Carcinoma Progression via Inflammasome Activation	Hyunjae Shin	Received

P-10	Early Nivolumab addition to Regorafenib in patients with Hepatocellular Carcinoma after first-line therapy (GOING trial).	Marco Sanduzzi-Zamparelli	Received

P-11	Updated Prospective Analysis of Hepatic and Extrahepatic Cancer Risk in Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir: Insights from the SAINT Cohort	Sung-Eun Kim	Received

P-12	Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma: Long-term survival in the LEAP-002 study	Richard Finn	Received

P-13	Aspirin and HCC risk in MASLD: Nationwide cohort study with genetic risk analysis	Hyunjae Shin	Received

P-14	Overall survival among 4913 patients with hepatocellular carcinoma treated with external beam radiation therapy: individual patient data outcomes from a multinational cohort	Andrew Moon	Received

P-15	Evolution of second-line practices in the era of immunotherapy: real-life data from the French prospective CHIEF cohort	Marie DECRAECKER	Received

P-16	Extended Follow-Up at 42 months of Atezolizumab–Bevacizumab in Advanced HCC: Insights from the CHIEF Prospective Study	Manon ALLAIRE	Received

P-17	Long - Chain Acyl - CoA Synthetase 4 (ACSL4): A Newly - Identified Driver at the Hepatocellular Carcinoma Invasive Front Governing Tumor Invasion, Metastasis and Patient Prognosis	Yusufukadier Maimaitinijiati	Received

P-19	ASH1L as a key driver of early hepatocarcinogenesis and a potential biomarker for early detection	Ji-Hye Oh	Received

P-21	A 7-serum-protein signature predicts response to atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma	Ranjeet Singh	Received

P-22	Early Detection of Hepatocellular Carcinoma Using a Machine Learning-based Methylation Blood Test	Eun Ju Cho	Received

P-23	Kinase Suppressor of Ras 1 promotes carcinogenesis in liver via collaborating with c-Myc	Hyuk Moon	Received

P-24	Deciphering the peripheral immune microenvironment via single-cell transcriptomics in hepatocellular carcinoma patients under atezolizumab-bevacizumab immunotherapy	Mónica Higuera	Received

P-26	The augmented natural killer (NK) cell-mediated cytotoxicity against hepatic stellate cells can effectively inhibit liver fibrosis and also improve survival in the patients with hepatocellular carcinoma	Jooho LEE	Received

P-27	Hybrid RNA sequencing revealed a tumor-associated FCGRT isoform in primary HCC	Piaorong Mei	Received

P-28	Association between gut microbial dynamics and clinical outcomes in patients with HCC receiving TACE: a prospective study	Jiwon Yang	Received

P-29	Lipophilic Statin Increases Sensitivity for Anticancer Therapy by Suppressing YAP/TAZ in the Experimental Hepatocellular Carcinoma Models	Jun Yong Park	Received

P-30	PD1+CD4+ central memory T cells predict early recurrence of hepatocellular carcinoma following percutaneous thermal ablation	Zuzana MacekJílková	Received

P-33	Association of TNFSF15 gene polymorphisms with the progression of hepatocellular carcinoma	Kuan-Chun Hsueh	Received

P-34	Taurocholic acid-decreased Lactobacillus intestinalis inhibit hepatocellular carcinoma antitumor immunity via a 5-HT/RORA/STING Signaling	Jingyuan Wen	Received

P-35	Integrative single-cell RNA sequencing unveils molecular parallels between circulating tumor cells and tumor nuclei in hepatocellular carcinoma	Mónica Higuera	Received

P-37	Establishment of novel multi-species hepatocellular carcinoma models: a cross-species exploration from mice to miniature pigs	Lichao Yang	Received

P-38	Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors	Yingcheng Wu	Received

P-41	Novel approaches that target post-proline proteases to treat syngeneic experimental liver tumours	JiaLi Huang	Received

P-43	RNA binding protein TIA1 Protects Hepatic Lipid Homeostasis and Prevents NAFLD-HCC through stress granule assembly	Rong Liu	Received

P-47	Primary Liver Cancers in France: Delayed Diagnosis of Underlying Liver Disease is the Main Barrier to First-Line Curative Treatment	charlotte COSTENTIN	Received

P-48	Predicting hepatocellular carcinoma recurrence after liver transplant with a multimodal residual-network random survival forest deep transfer learning model	Rex Wan-Hin Hui	Received

P-49	Impact of deprivation on HCC patient outcomes at The Royal Free Hospital between 2014-2023	ALEXA CHILDS	Received

P-50	Machine learning models to predict HCC recurrence after liver transplantation	Anja Lachenmayer	Received

P-52	Prognostic impact of tumor-associated endothelial B7-H3 expression in hepatocellular carcinoma	Yunmi Ko	Received

P-53	Distribution and Survival Association of Genetic Polymorphisms in Thai Patients with Hepatocellular Carcinoma According to Underlying Liver Disease	Theint Cho Zin Aung	Received

P-54	Sex Matters in HCC Management: Evidence from a Nationwide French Cohort	charlotte COSTENTIN	Received

P-55	Mortality and Cardiovascular Outcomes in Patients with MAFLD versus MASLD: A Systematic Review and Meta-Analysis	Jiwon Yang	Received

P-56	Relationship of progression and recurrence with OS in Real-World Patients with Embolization-Eligible HCC Treated with LRT	Kyungeun Lee	Received

P-57	Aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study and a genetic causality analysis	Moon Haeng Hur	Received

P-58	Clinical significance of citrullinated glial fibrillary acidic protein in predicting outcomes in hepatocellular carcinoma	Sung-Eun Kim	Received

P-59	Prognostic Significance of Tumor Budding in Hepatocellular Carcinoma Patients Treated with Neoadjuvant and Conversion Therapy: A Cohort Study of 225 Cases Using Modified ITBCC Criteria	Puwen Shen	Received

P-60	Treatment outcomes of systemic therapies: infiltrative vs. multinodular hepatocellular carcinoma	Yu-Yun Shao	Received

P-62	A Novel Surveillance Model Utilizing Liquid Biopsy and Tumor Markers, enhanced by Machine Learning, for Diagnosing Chronic Liver Disease and Hepatocellular Carcinoma in the General Population	Yuki Kunimune	Received

P-63	Enhanced prediction of HBV-Related HCC using aMAP and liver stiffness assessed by Vibration-Controlled Transient Elastography	Hye Yeon Chon	Received

P-64	Detection and monitoring of HBV-related hepatocellular carcinoma from plasma cfDNA fragmentation profiles	Pin Cui	Received

P-68	High-throughput plasma DNA methylation signature testing for diagnosis of hepatocellular carcinoma	Rex Wan-Hin Hui	Received

P-70	Deep learning for hepatocellular carcinoma differentiation grading in digitized whole slide images: transformers as superior feature aggregators	Yan Miao	Received

P-71	Impact of Arterial Phase Motion Artifacts on LI-RADS Categorization: Intraindividual Comparison Between Hepatobiliary and Extracellular Contrast MRI in Surgically Proven HCC	Jeong Ah Hwang	Received

P-72	Noncontrast Abbreviated MRI for Surveillance of Recurrent Hepatocellular Carcinoma After Tansarterial Chemoembolization	Sun Kyung Jeon	Received

P-73	Immune Checkpoint Inhibitors as a Downstaging Strategy for Barcelona Clinic Liver Cancer Stage B and C Hepatocellular Carcinoma (A Study by LIFT-HCC Consortium)	Ju dong Yang	Received

P-74	Selective Internal Radiation Therapy Combined with Immunotherapy (SIRT-ICI) in Locally Advanced Hepatocellular Carcinoma (HCC): A Western Pilot Study	Christian Hobeika	Received

P-82	Exploratory results on the efficacy and safety of Atezolizumab plus Bevacizumab (atezo/bev) as conversion therapy in hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI) in the TALENTop study	Tianqiang Song	Received

P-83	Exosomal miR-30a-5p Decision Tree for Predicting Response to Atezolizumab and Bevacizumab in Hepatocellular Carcinoma	Youngwoo Lee	Received

P-84	Adverse Event Monitoring with Imaging: Prognostic Significance in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma	Jeayeon Park	Received

P-85	Neoadjuvant and adjuvant nivolumab associated with curative-intent percutaneous irreversible electroporation in patients with BCLC A hepatocellular carcinoma: final results of the NIVOLEP NCT03630640 trial	Pierre Nahon	Received

P-87	Heterogeneity of 16S rRNA gene variable regions in oral & gut microbiota of patients receiving chemotherapy for biliary tract cancer (EMBRACER study)	Roseanna Wheatley	Received

P-88	Efficacy and safety of Selective Internal Radiation Therapy (SIRT) combined with chemotherapy and immunotherapy in locally advanced intrahepatic cholangiocarcinoma	Maxime REMOND	Received

P-89	Therapeutic Targeting of CD44E Isoform with CAR-T Cells in Hepatocellular Carcinoma	Shanglin Li	Received

P-90	Comprehensive analysis of the TALENTRUE study in patients with initially unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab combined with transarterial chemoembolization as conversion therapy in real-world practice	Linsen Ye	Received

P-92	Usefulness of Methylated Somatostatin in Predicting Treatment Response to Atezolizumab Plus Bevacizumab Therapy in Patients with Hepatocellular Carcinoma	Maho Egusa	Received

P-95	Development and Validation of a Risk Prediction Model for Patients with Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab	Heechul Nam	Received

P-96	Efficacy of LEN–New FP Therapy for Unresectable Hepatocellular Carcinoma: A Promising Salvage Treatment for Systemic Therapy-Resistant or -Intolerant Cases	Susumu Maruta	Received

P-98	Hepatocellular Carcinoma and Liver Transplantation in Romania: Insights from Over Two Decades of Clinical Experience	Speranta Iacob	Received

P-101	Progression free survival after completion of 2 years therapy of atezolizumab plus bevacizumab (Ate+Beva) depend on tumor response at the time of discontinuation of Ate+Beva.	SANGYOUN HWANG	Received

P-102	Monitoring T cell function in patients with unresectable hepatocellular carcinoma (uHCC) who received atezolizumab (atezo) plus bevacizumab (bev): feasibility of developing biomarkers using blood samples	Chiun Hsu	Received

P-103	Anti-angiogenic Adverse Events and Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma treated with first-line Atezolizumab-Bevacizumab: A Landmark Analysis	Joycelyn Lee	Received

P-104	Radiotherapy for patients over 70 years old with liver-confined hepatocellular carcinoma	SUN HYUN BAE	Received

P-106	A Study of the Efficacy and Safety of Hepatocellular Carcinoma Treatment by Radiofrequency Ablation with D-Sorbitol	RYOSUKE IMADO	Received

P-107	Combination of Hepatic Arterial Infusion Chemotherapy with Tyrosine Kinase Inhibitor Provides Better Survival in Advanced Hepatocellular Carcinoma Patients	Po Ting Lin	Received

P-108	Comparison of Treatment Efficacy and Safety Profile of Atezolizumab Plus Bevacizumab in BCLC B and C Patients with Hepatocellular Carcinoma	Jae Hyun Yoon	Received

P-110	Efficacy and Safety of atezolizumab/bevacizumab in patients with hepatocelullar carcinoma: a real world retrospective cohort	Jose Luis Lledó	Received

P-111	Efficacy of First-Line Atezolizumab Plus Bevacizumab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Real-World Study	Yijun Lu	Received

P-112	Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: Real-World Evidence from a Large-Scale Multicenter Study	Guohong Han	Received

P-114	Neoadjuvant therapy for hepatocellular carcinoma with tumor–hepatic vein detachment	Haiqing Wang	Received

P-116	Hepatic Resection Versus Stereotactic Body Radiation Therapy for BCLC Stage 0 Hepatocellular Carcinoma: A Propensity-Weighted Analysis	Sang Min Yoon	Received

P-117	Risk Factors influencing Prognosis in Patients with Fibrolamellar Hepatocellular Carcinoma.	Elena Antonova	Received

P-118	Transarterial Chemoembolization Alone or in Combination with Radiotherapy as First-Line Treatment for BCLC Stage 0–A Single Hepatocellular Carcinoma	Hye In Lee	Received

P-119	Depth of Tumor Marker Response as a Predictor of Treatment Response in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab	Issei Saeki	Received

P-120	Outcomes of Liver Transplantation in Patients with BCLC Stage D Hepatocellular Carcinoma	Hongzhao Yang	Received

P-121	Clinical outcome of cabozantinib in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors	Kaoru Tsuchiya	Received

P-124	Comparison of three methods for mapping organs at risk (OARs) in patients with liver cancer	Pei-Jin Tsai	Received

P-127	The impacts of human albumin on postoperative clinical outcomes in Chinese HCC patients treated with surgical operation: the REAL study	Tian He	Received

P-128	Hepatocellular Carcinoma Occurrence and Recurrence After Direct-Acting Antiviral Treatment for Hepatitis C: Predictive Factors and Outcomes	HIROKI TAI	Received

P-129	A phase 1 clinical trial of the small molecule dual degrader of GSPT1 and NEK7 proteins alone and in combination with everolimus for the treatment of hepatocellular carcinoma.	Robert Dyjas	Received

P-130	Efficacy of Combined Three-Dimensional Conformal Radiotherapy and Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion	JOJI TANI	Received

P-132	A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with Activating FGF/FGFR Pathway Aberrations (SURF431)	Lipika Goyal	Received

P-133	Radiological Response to trans-arterial chemoembolization is associated with the outcomes of Liver Transplantation in HCC Patients: A Multicentre Cohort Study	Marco Dioguardi Burgio	Received

P-137	Second-Line HAIC Achieves Higher Intrahepatic Disease Control than TKIs after Atezolizumab plus Bevacizumab Failure in Hepatocellular Carcinoma	Deok Hwa Seo	Received

P-138	Soluble FAP amplifies a FAP–STAT3 positive feedback loop in hepatocellular carcinoma cancer associated fibroblasts by upregulating PDGFRB	Deok Hwa Seo	Received

ILCA 2025 Annual Conference

19 - 21 November, 2025. Hong Kong

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 19/11/2025 TO 19/11/2026

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access